about
Variant of TYR and autoimmunity susceptibility loci in generalized vitiligoGenome-wide association analyses identify 13 new susceptibility loci for generalized vitiligoThe transcription factors SOX9 and SOX10 are vitiligo autoantigens in autoimmune polyendocrine syndrome type I.Mapping of human autoantibody binding sites on the calcium-sensing receptor.Autoantigens in vitiligo identified by the serological selection of a phage-displayed melanocyte cDNA expression library.Common variants in FOXP1 are associated with generalized vitiligo.Autoantibodies in vitiligo patients recognize multiple domains of the melanin-concentrating hormone receptor.Autoimmune hypocalciuric hypercalcemia unresponsive to glucocorticoid therapy in a patient with blocking autoantibodies against the calcium-sensing receptorComprehensive association analysis of candidate genes for generalized vitiligo supports XBP1, FOXP3, and TSLP.PRKDC mutations associated with immunodeficiency, granuloma, and autoimmune regulator-dependent autoimmunity.Autoantibodies as diagnostic and predictive markers of vitiligo.Is there loss or qualitative changes in the expression of thyroid peroxidase protein in thyroid epithelial cancer?Autoantibody responses to melanocytes in the depigmenting skin disease vitiligo.Melanin-concentrating hormone and melanin-concentrating hormone receptors in mammalian skin physiopathology.Induction of regulatory T cells: A role for probiotics and prebiotics to suppress autoimmunity.Localization of GerAA and GerAC germination proteins in the Bacillus subtilis spore.Serological proteome analysis reveals new specific biases in the IgM and IgG autoantibody repertoires in autoimmune polyendocrine syndrome type 1.Development of a 3D human in vitro skin co-culture model for detecting irritants in real-time.The calcium-sensing receptor is a target of autoantibodies in patients with autoimmune polyendocrine syndrome type 1.Autoantibodies in vitiligo patients are not directed to the melanocyte differentiation antigen MelanA/MART1.Vitiligo patients from India (Mumbai) show differences in clinical, demographic and autoantibody profiles compared to patients in western countries.Autoantibodies against the calcium-sensing receptor and cytokines in autoimmune polyglandular syndromes types 2, 3 and 4.Tumour necrosis factor-α antagonists as therapies for vitiligo.The CC genotype of the ERCC1 C118T single-nucleotide polymorphism impacts positively on the efficacy of narrowband ultraviolet B therapy for vitiligo.International survey on high- and low-dose synacthen test and assessment of accuracy in preparing low-dose synacthen.Alteration of Immune-Mechanisms by Human Microbiota and Development and Prevention of Human Diseases.Structural insights into autoreactive determinants in thyroid peroxidase composed of discontinuous and multiple key contact amino acid residues contributing to epitopes recognized by patients' autoantibodies.The antibody response against MART-1 differs in patients with melanoma-associated leucoderma and vitiligo.Autoantibodies against tyrosine hydroxylase in patients with non-segmental (generalised) vitiligoAssociation analysis of the cytotoxic T lymphocyte antigen-4 (CTLA-4) and autoimmune regulator-1 (AIRE-1) genes in sporadic autoimmune Addison's diseaseAnalysis of a microsatellite polymorphism of the cytotoxic T-lymphocyte antigen-4 gene in patients with vitiligoA cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism is associated with autoimmune Addison's disease in English patientsImmunosuppressive therapy of autoimmune hypoparathyroidism in a patient with activating autoantibodies against the calcium-sensing receptorSevere Symptomatic Hypocalcemia from HIV Related HypoparathyroidismCalcium-Sensing Receptor Autoantibodies in Patients with Autoimmune Polyendocrine Syndrome Type 1: Epitopes, Specificity, Functional Affinity, IgG Subclass, and Effects on Receptor ActivityMelanocyte antigen-specific antibodies cannot be used as markers for recent disease activity in patients with vitiligoViewpoint 1Immunoglobulin G kappa antithyroid peroxidase antibodies in Hashimoto's thyroiditis: epitope-mapping analysisDetection of binding and blocking autoantibodies to the human sodium-iodide symporter in patients with autoimmune thyroid diseaseAutoantibodies to the flavoprotein subunit of succinate dehydrogenase: analysis of specificity in autoimmune thyroid disease
P50
Q24629443-DB5C1DD0-1061-466E-96FC-B57F1BE95840Q28924362-A21E3093-7D44-4048-8242-F0692EE7B91FQ30681365-7875DB4C-4E69-48AE-AB98-CA8A247F9DCAQ33478693-B8734539-07C1-46BA-8B38-E3FCE658A841Q33479966-604356D8-99CF-4BA2-9F45-7323A683F9C9Q33945522-2D7CAF95-3ADD-4FC1-B7D4-45888BE9CD61Q34278360-7EFC0102-0766-4848-B854-6DD729737189Q34617181-9BDBEA22-29BD-4A3F-ADD8-F3CEC9482EE0Q35212048-B761A20A-DD66-4DFE-8621-6F06DF9C8F2BQ35806314-2493B300-AB47-4C18-A7F8-B567A4079325Q35934690-37CC1046-5321-4EEE-9007-981244B5AA94Q36643368-26E03C79-A02F-4322-B102-A7D9BFAAD729Q36731840-8CB65860-B9E8-4D0E-87B0-2F0210224F42Q37482504-8944804E-7488-4C1D-8AB5-12029903DD56Q38698750-CFC5E48B-58C4-45BA-95BC-3C50A42FE27AQ39504214-702BCD65-7079-4520-B321-7F407EF00196Q40601989-801496E8-B0BD-4594-B5B4-9B914FB84710Q43011486-EDEEDCA3-7DE7-4C51-9813-848A2C44EA76Q43717357-F9174C84-3423-486C-A518-10FF5EE9D984Q44116002-D5AF4E35-D1AB-4DAD-A0E2-1E974E6EAF4EQ46953146-2E5C0C1A-38D8-47CB-99D2-F89D681AB7BAQ47755527-77AF7BB0-2060-4E8C-9178-DCFC46378D13Q48128928-88CFEE87-96D3-4C0C-B0DE-5DFF9ED97ED9Q48136717-39B6E49F-2C82-4021-9F08-89803BA19EEEQ48508373-E9BE0245-5569-4026-A980-C3551DB96F9FQ49527824-894B3253-39A0-4AA6-8594-CA85DE07E134Q51804167-2DF47025-8A7F-45D9-8F90-C57719F0863BQ55058396-A1F57562-09DE-4A9F-B45C-CAA07392FF10Q56892977-0C358537-53BD-4EB6-8D8E-0A6CDC001ABCQ56906268-DEF28A99-969C-453B-9196-F97206109066Q56907304-49FB523C-1EC1-4460-8D27-FE81D2783075Q56907420-10C56F92-1B5E-4B59-8BF7-8128BAFCE487Q57785190-6D59CC16-D505-4EFE-A539-02FC467B458EQ57821415-4F4A78E9-FF5B-4847-B3EA-488FC114B9A8Q58088891-17729449-49FA-4FC6-8CA2-69E60F222C09Q60628782-804ED58A-3283-462C-B18B-C5933DA97EFCQ60628791-ECBB705C-181C-425A-8CE6-93CCF7C4BC52Q73578124-733757B7-4B4C-46A8-99BD-6D4A3418A4A3Q73867066-0973B4CD-F5B2-4BE3-8C11-175E01545CDFQ74261015-AC9A73D0-A6E9-43F8-98D9-162753F81CC8
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Elizabeth Helen Kemp
@ast
Elizabeth Helen Kemp
@en
Elizabeth Helen Kemp
@es
Elizabeth Helen Kemp
@nl
type
label
Elizabeth Helen Kemp
@ast
Elizabeth Helen Kemp
@en
Elizabeth Helen Kemp
@es
Elizabeth Helen Kemp
@nl
altLabel
E H Kemp
@en
prefLabel
Elizabeth Helen Kemp
@ast
Elizabeth Helen Kemp
@en
Elizabeth Helen Kemp
@es
Elizabeth Helen Kemp
@nl
P1053
D-1665-2011
P106
P1153
55665136000
P31
P496
0000-0002-0313-8916